Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.3839
Abstract: Importance Recent national guidelines recommend sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD); yet, there are limited data on… read more here.
Keywords: disease; use; sodium glucose; sglt2i glp ... See more keywords
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-01154-w
Abstract: The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at… read more here.
Keywords: risk; high risk; sglt2i glp; type diabetes ... See more keywords
1474-P: Changes in SGLT2i and GLP-1RA Real-World Initiator Profiles following Cardiovascular Outcome Trials—A Danish Nationwide Population-Based Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1474-p
Abstract: Objectives: To investigate changes in clinical characteristics of SGLT2i and GLP-1RA initiators in Denmark before/after landmark trials. Materials and Methods: Compared first-time SGLT2i (25,070) and GLP-1RA (15,803) initiators to initiators of DPP-4i (without proven cardiovascular… read more here.
Keywords: sglt2i glp; glp 1ra; glp; boehringer ingelheim ... See more keywords
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1113
Abstract: OBJECTIVES To assess associations between current use of sodium-glucose cotransporter 2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP-1RAs), and their combination and risk for major adverse cardiac and cerebrovascular events (MACCE) and heart failure… read more here.
Keywords: glp 1ra; combination; type diabetes; primary prevention ... See more keywords
Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc22-0570
Abstract: OBJECTIVE Patients with type 2 diabetes undergoing coronary artery bypass grafting (CABG) are at risk for cardiovascular events. Sodium-glucose cotransporter 2 receptor inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) are effective cardioprotective agents;… read more here.
Keywords: glp; glp 1ra; bypass grafting; coronary artery ... See more keywords
Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.936651
Abstract: Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports… read more here.
Keywords: sglt inhibitors; prescription; glp receptor; online searches ... See more keywords